GALE-301 is under clinical development by SELLAS Life Sciences Group and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect GALE-301’s likelihood of approval (LoA) and phase transition for Peritoneal Cancer took place on 17 Nov 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their GALE-301 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

GALE-301 overview

GALE-301 is under development for the treatment of ovarian, breast, endometrial, fallopian and peritoneal cancer. The vaccine candidate is administered intradermally. The drug candidate is a vaccine against E39 peptide derived from the folate binding protein (fbp) and combined with the immune adjuvant granulocyte macrophage colony stimulating factor (GM-CSF). It is developed based on RNA-targeted and immunotherapy technology.

SELLAS Life Sciences Group overview

SELLAS Life Sciences Group (SELLAS), formerly Galena Biopharma, develops novel cancer immunotherapeutics for multiple cancer treatments. Its pipeline product candidates include galinpepimut-S (GPS), a wilms tumor1 (WT1) protein-targeting synthetic heteroclitic epitope immunotherapeutic antigen used for the treatment of acute myeloid leukemia, ovarian cancer, malignant pleural mesothelioma, multiple myeloma and solid tumors; and Nelipepimut-S, a vaccine derived from the human epidermal growth factor 2 or HER2 protein for the prevention of breast cancer and gastric carcinomas. The company collaborates with Memorial Sloan Kettering Cancer Center (MSKCC), National Cancer Institute (NCI) and The University of Texas M.D. Anderson Cancer Center (MDACC) for conducting clinical trials targeting multiple cancer indications. SELLAS is headquartered in New York City, New York, the US.

Quick View GALE-301 LOA Data

Report Segments
  • Innovator
Drug Name
  • GALE-301
Administration Pathway
  • Intradermal
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: SELLAS Life Sciences Group
  • Originator: Henry M Jackson Foundation for the Advancement of Military Medicine and University of Texas MD Anderson Cancer Center
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.